Rep. Kevin Hern Sells Off Shares of Danaher Corporation (NYSE:DHR)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Danaher Corporation (NYSE:DHR). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Danaher stock on September 2nd. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Danaher Stock Performance

Shares of DHR stock traded down $2.32 during midday trading on Tuesday, hitting $225.01. 1,531,254 shares of the company were exchanged, compared to its average volume of 4,456,594. The firm has a market capitalization of $158.18 billion, a P/E ratio of 39.87, a PEG ratio of 2.80 and a beta of 0.78. The firm’s 50 day moving average price is $206.57 and its two-hundred day moving average price is $192.90. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.77 EPS. As a group, equities research analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Hedge Funds Weigh In On Danaher

A number of hedge funds have recently bought and sold shares of DHR. BlackRock Inc. purchased a new stake in shares of Danaher in the second quarter worth $10,492,520,000. Norges Bank bought a new stake in Danaher in the fourth quarter worth $2,177,106,000. Jupiter Topco LLC bought a new stake in shares of Danaher in the 2nd quarter worth about $1,456,317,000. Generation Investment Management LLP bought a new position in shares of Danaher in the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE bought a new position in Danaher in the 2nd quarter worth about $993,846,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the subject of several recent analyst reports. UBS Group initiated coverage on Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price for the company. HSBC lowered their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Royal Bank Of Canada boosted their target price on shares of Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 22nd. Evercore reiterated an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Finally, Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $230.23.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.